High mRNA expression of PLCB2 was associated with a poor OS of every NSCLC patient (p = 0.00047, HR = 1.25, 95% CI = 1.1–1.42; Figure 8(a)), while elevated mRNA expression of PLCB2 was associated with the worse OS of AC patients (p = 5.8e−07, HR = 1.8, 95% CI = 1.42–2.27; Figure 8(b)), as well as SCC patients (p = 0.42, HR = 1.1, 95% CI = 0.86–1.39; Figure 8(c)). This evidence concerns the gene PLCB2 and non-small cell lung carcinoma.